



Designation: F1609 – 23

Standard Specification for Calcium Phosphate Coatings for Implantable Materials¹

This standard is issued under the fixed designation F1609; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This specification covers the material requirements for calcium phosphate coatings for surgical implant applications.

1.2 In particulate and monolithic form, the calcium phosphate materials system has been well characterized regarding biological response (**1, 2**)² and laboratory characterization (**2-4**). Several publications (**5-10**) have documented the *in vitro* and *in vivo* properties of selected calcium phosphate coating systems.

1.3 This specification covers hydroxylapatite coatings, other calcium phosphate (for example, octacalcium calcium phosphate, amorphous calcium phosphate, dicalcium phosphate dihydrate) coatings, or a coating containing a combination of two or more calcium phosphate phases, with or without intentional minor additions of other elements or compounds (for example, fluorine, manganese, magnesium, carbonate),³ and applied by methods including, but not limited to, the following: (1) plasma spray deposition, (2) solution precipitation, (3) dipping/sintering, (4) electrophoretic deposition, and (5) sputtering.

1.4 For a coating containing two or more calcium phosphate phases, one or more of which will be a major phase or major phases in the coating, while the other phase(s) may occur as a second or minor phases, the phase composition(s) of the coating should be determined against each corresponding crystalline phase, respectively. See **X1.2**.

1.5 Substrates may include smooth, porous, textured, and other implantable topographical forms.

1.6 This specification excludes organic coatings that may contain calcium and phosphate ionic species.

1.7 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

2. Referenced Documents

2.1 ASTM Standards:⁴

E376 Practice for Measuring Coating Thickness by Magnetic-Field or Eddy Current (Electromagnetic) Testing Methods

F1044 Test Method for Shear Testing of Calcium Phosphate Coatings and Metallic Coatings

F1088 Specification for Medical-Grade Beta-Tricalcium Phosphate Raw Material for Implantable Medical Devices

F1147 Test Method for Tension Testing of Calcium Phosphate and Metallic Coatings

F1160 Test Method for Shear and Bending Fatigue Testing of Calcium Phosphate and Metallic Medical and Composite Calcium Phosphate/Metallic Coatings

F1185 Specification for Composition of Medical-Grade Hydroxylapatite for Surgical Implants

F1854 Test Method for Stereological Evaluation of Porous Coatings on Medical Implants

F1926 Test Method for Dissolution Testing of Calcium Phosphate Granules, Fabricated Forms, and Coatings

F2024 Practice for X-ray Diffraction Determination of Phase Content of Plasma-Sprayed Hydroxyapatite Coatings

2.2 U.S. Pharmacopeia Convention Documents:⁵

National Formulary XVI Tribasic Calcium Phosphate

USP <191> Chemical Tests—Calcium and Phosphorous

USP <211> Arsenic

USP <232> Elemental Impurities—Limits

USP <233> Elemental Impurities—Procedures

USP <251> Lead

USP <261> Mercury

¹ This specification is under the jurisdiction of ASTM Committee **F04** on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee **F04.13** on Ceramic Materials.

Current edition approved July 1, 2023. Published July 2023. Originally approved in 1995. Last previous edition approved in 2014 as F1609 – 08 (2014). DOI: 10.1520/F1609-23.

² The boldface numbers in parentheses refer to the list of references at the end of this specification.

³ The Joint Committee on Powdered Diffraction has established a Powder Diffraction File. The committee operates on an international basis and cooperates closely with the Data Commission of the International Union of Crystallography and ASTM. Hydroxylapatite data can be found on file card No. 9-432; beta tricalcium phosphate data can be found on file card No. 9-169.

⁴ For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

⁵ Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, <http://www.usp.org>.

2.3 Other Documents:

U.S. Geological Survey Method Cadmium⁶

U.S. Code of Federal Regulations Title 21 (CFR 21), Part 820 Quality System Regulation⁷

X-Ray Diffraction Analyses³

ICH Q3D ICH Harmonized Guideline for Elemental Impurities⁸

3. Terminology

3.1 Definitions:

3.1.1 *amorphous calcium phosphate*—a non-crystalline calcium phosphate.

3.1.2 *beta tricalcium phosphate*—a calcium phosphate substance of empirical chemical formula, $\text{Ca}_3(\text{PO}_4)_2$ (see Specification F1088).

3.1.3 *calcium phosphate*—any one of a number of inorganic chemical compounds containing calcium and phosphate ions as its principal constituents.

3.1.4 *coating*—a layer of mechanically or chemically attached material covering a substrate material.

3.1.5 *hydroxylapatite*—a calcium phosphate crystalline compound of empirical chemical formula, $\text{Ca}_5(\text{PO}_4)_3\text{OH}$ (see Specification F1185).

4. Chemical or Crystallographic Requirements, or Both

4.1 Chemical:

4.1.1 Elemental analysis for calcium and phosphorous and intentional additions (other than elemental impurities) shall be consistent with the expected stoichiometry of the specific calcium phosphate compound(s). The calcium and phosphorus content shall be determined using a suitable method such as USP <191> Identification Tests for Calcium and Phosphate, USP <232> Elemental Impurities—Limits, and USP <233> Elemental Impurities—Procedure (see 2.2) or X-ray fluorescence.

4.1.2 The analysis of elemental impurities may be required, based on the conditions, apparatus, or environments specific to the coating application technique used.

4.1.2.1 The significance of elemental impurities within an absorbable material is ultimately dependent on the dimensional characteristics of the final product and the rate of release of those initially interstitial elements into the surrounding tissue and extracellular fluid. Thus, any risk assessment of such impurities will be dependent on the final product design and intended application. More detailed and pharmaceutical-oriented guidance regarding the appropriate means for both monitoring and assessing relevant elemental impurities within

a final product can be found in USP Chapters <232> and <233> and in the ICH Harmonised Guideline for Elemental Impurities—Q3D.

4.1.2.2 Determine the concentration of the respective elemental impurities within the coating by utilizing inductively coupled plasma mass spectroscopy (ICP-MS) or inductively coupled plasma atomic or optical emission spectroscopy (ICP-AES or ICP-OES) or an equivalent alternative method as described in Chapter <233> of the U.S. Pharmacopeia. The specific 24 different elemental impurities of interest are outlined in both USP <232> and in Table A.2.2 of the ICH Harmonised Guideline for Elemental Impurities—Q3D. Both of these documents include risk-based approaches toward the assessment and control of elemental impurities.

4.1.2.3 Except for intentionally added elements, assess the obtained results for compliance with the Parenteral Concentration limits described within the Individual Component Option of USP <232>, Table 3 (derived from ICH Q3D Option 1, Table A.2.2). If all listed elements except for those that are intentionally added can be assured to be maintained within the Parenteral Concentration Individual Component Option limits, the material “conforms” to the USP <232> elemental impurities limits (except for those intentionally added). If any listed element (other than those intentionally added) cannot be controlled to be maintained within the prescribed USP <232> limits, the material does not conform with the USP <232> elemental impurities limits and the concentration (in ppm, per USP <233> or equivalent) of each uncontrolled element shall be both monitored and reported.

4.1.2.4 The elemental impurities thresholds for the Individual Component Option of USP <232>, Table 3, provide specific elemental daily dosage limits for parenteral drug products. These daily elemental impurity limits (including those applied to intentionally added elements) should be considered as conservative thresholds for informational purposes only when applied to absorbable implants. Proper application of these limits in setting material specifications should consider the amount of the coating in the final implant product as well as its degradation and elemental elution rate into the surrounding tissue.

4.1.2.5 The elemental impurity content of the coating used in implants with a successful clinical history may also be considered in setting limits for material specifications. For such data to be relevant, analyses shall be consistent with the methods of USP <233> and shall be conducted on raw material lots used for clinically released product.

4.1.3 The analysis of intentional additional elements or compounds such as fluorine, manganese, magnesium, carbonate, and so forth shall be specified (concentration in ppm, per USP <233> or equivalent) for calcium phosphate coatings.

4.1.4 Calcium to phosphorus ratio (Ca/P) shall be performed on both the powder and coating forms using a suitable method.

4.2 Crystallographic Characterization:

4.2.1 Crystallographic characterization shall be in accordance with Practice F2024.

⁶ Crock, J. G., Felichte, F. E., and Briggs, P. H., “Determination of Elements in National Bureau of Standards Geological Reference Materials SRM 278 Obsidian and SRM 688 Basalt by Inductively Coupled Argon Plasma—Atomic Emission Spectrometry,” *Geostandards Newsletter*, Vol 7, 1983, pp. 335–340.

⁷ Available from Standardization Documents Order Desk, DODSSP, Bldg. 4, Section D, 700 Robbins Ave., Philadelphia, PA 19111-5098, <http://dodssp.daps.dla.mil>.

⁸ Available from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), ICH Secretariat, Route de Pré-Bois, 20, P.O. Box 1894, 1215 Geneva, Switzerland, <https://www.ich.org>.